Evommune

Palo Alto, CA

Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases.

Claim this profile

Employbl Premium

Get the inside track on Evommune

Premium profiles, AI research on tech stack and hiring, 61,000+ ATS job listings, saved searches, and an AI chat that knows the SF startup scene.

AI chat about Evommune's culture, stack, and interview process
Save jobs and get alerts on new openings
Full premium profiles across our company index
7-day free trial, then $25/mo. Cancel anytime.

Start free trial →Already have an account? Sign in

Company Details

Founded: 2020
Employees: Between 20 - 50 employees
Raised: $349,799,936
Headquarters Location: Palo Alto, CA
Public: No
Acquired: No
CEO: Luis Pena
Founders: Hans Hofland
Luis Pena

Company Collections

These are collections Evommune is a part of. Click on the collection name to view similar companies.

Evommune's Industries

Software Companies

Medical Organizations

Biotechnology Companies

Evommune's Tech Stack

Amazon Web Services

Microsoft Azure

Evommune Headquarters Location

Palo Alto, CA 94306

Total Amount Raised: $349,799,936

Evommune Funding Rounds

Post Ipo Equity
$125,000,000
Feb 12, 2026
Series Unknown
$81,799,952
Jan 7, 2025
Series Unknown
$81,799,952
Jan 6, 2025
IPO
Unknown
Jan 1, 2025
Series C
$115,000,000
Oct 31, 2024
Series C
$115,000,000
Oct 30, 2024
Series C Investors
RA Capital Management
Sectoral Asset Management
Allostery Investments
Pivotal bioVenture Partners
ADAR1 Capital Management
Verition Fund Management
Amplitude Ventures
LSP
B Capital
Andera Partners
FemHealth Ventures
SymBiosis
Avego Bioscience Capital
Marshall Wace
Longwood Fund
RTW Investments
NEXTBio Capital
Oscar & Paul
Series B
$7,500,000
Jun 28, 2023
Series B
$7,500,000
Jun 27, 2023
Series B Investors
Verition Fund Management
Series B
$50,000,000
Apr 26, 2023
Series B
$50,000,000
Apr 25, 2023
Series B Investors
Arix Bioscience
LSP
SymBiosis
Amplitude Ventures
Andera Partners
Pivotal bioVenture Partners
Series A
$83,000,000
Sep 9, 2021
Series A
$83,000,000
Sep 8, 2021
Series A Investors
Pivotal bioVenture Partners
Andera Partners
LSP BioVentures
Seed
$12,500,000
Nov 18, 2020
Seed
$12,500,000
Nov 17, 2020
Seed Investors
Pivotal bioVenture Partners

Funding info provided by Diffbot.

Evommune Reviews

Based on 0 reviews

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Evommune.